Specialized Hospital For Active Treatment Of Pneumo-Physiatiric Diseases Vraca /Sbalpfz Vratsa EOOD

At the Specialized Hospital For Active Treatment Of Pneumo-Physiatiric Diseases Vraca /Sbalpfz Vratsa EOOD, most studies focus on respiratory tract diseases, especially asthma, chronic obstructive pulmonary disease, and bronchiectasis. The trials are designed to improve symptom control, reduce flare-ups, and test whether newer inhaled or biologic therapies can offer better long-term outcomes for people with persistent lung disease.

• Studies in asthma are looking at better control for moderate to severe and inadequately controlled disease
• Research in COPD is evaluating ways to reduce exacerbations and support breathing function
• Trials in bronchiectasis are testing treatments aimed at lowering pulmonary exacerbations

This work reflects a strong clinical interest in helping patients with chronic airway conditions through improved treatment effectiveness and disease management.

The site also conducts research in virus diseases, with attention to SARS-CoV-2 infection and related pediatric care. These trials explore antiviral treatment options and safety in younger patients, with the goal of supporting recovery and preventing progression to more severe illness.

• SARS-CoV-2 infection studies are assessing antiviral treatment use in children and adolescents
• Research is focused on safety, tolerability, and treatment effectiveness in nonhospitalized patients at risk
• The overall aim is to improve care for pediatric COVID-19 cases

These studies add an important infectious disease component to the Pneumology Department portfolio in Vratsa.

Another key area of research involves immune system phenomena, especially inflammation-driven disease patterns in asthma and COPD. Trials here are examining whether targeted therapies can better control airway inflammation, improve lung function, and reduce the risk of repeated exacerbations.

• In asthma, studies are evaluating control of inflammation and protection against lung function decline
• In COPD, research is testing approaches to reduce exacerbation frequency in patients with ongoing symptoms
• Some studies are exploring biomarkers such as FeNO to better understand treatment response

The research profile shows a clear emphasis on immune-linked respiratory conditions and the search for more precise, effective treatment strategies.